Publications by authors named "April Shamy"

Claim this Profile
P
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma.
Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, Richard LeBlanc, Julie Côté, April Shamy

Curr Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in quality of life in MDS patients who become transfusion independent after treatment.
Bo A Wan, Shabbir M H Alibhai, Lisa Chodirker, Lee Mozessohn, Michelle Geddes, April Shamy

Leuk Lymphoma· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.
Jennifer Teichman, Michelle Geddes, Nancy Zhu, Mary-Margaret Keating, Mitchell Sabloff, April Shamy

Haematologica· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Rena Buckstein, Lisa Chodirker, Lee Mozessohn, Karen W L Yee, Michelle Geddes, April Shamy

Leuk Lymphoma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.
Irina Amitai, Michelle Geddes, Nancy Zhu, Mary-Margaret Keating, Mitchell Sabloff, April Shamy

Br J Haematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revised 15-item MDS-specific frailty scale maintains prognostic potential.
Bo A Wan, Aziz Nazha, Rebecca Starkman, Shabbir Alibhai, Richard A Wells, April Shamy

Leukemia· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.
Heather A Leitch, Rena Buckstein, Nancy Zhu, Thomas J Nevill, Karen W L Yee, April Shamy

Leuk Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Brett L Houston, Jennifer Jayakar, Richard A Wells, Martha Lenis, Liying Zhang, April Shamy

Ann Hematol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Heather A Leitch, Ambica Parmar, Richard A Wells, Lisa Chodirker, Nancy Zhu, April Shamy

Br J Haematol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Rena Buckstein, Richard A Wells, Nancy Zhu, Heather A Leitch, Thomas J Nevill, April Shamy

Br J Haematol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.
Sara Samuel, Vladimir Beljanski, Julien Van Grevenynghe, Stephanie Richards, Fethia Ben Yebdri, April Shamy

Mol Ther· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
Heather A Leitch, Rena Buckstein, April Shamy, John M Storring

Crit Rev Oncol Hematol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.
Sara Samuel, Vanessa F Tumilasci, Stephanie Oliere, Thi Liên-Anh Nguyên, April Shamy

Mol Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.
Vanessa Fonseca Tumilasci, Stephanie Olière, Thi Lien-Ahn Nguyên, April Shamy, John Bell

J Virol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis